Ir para o conteúdo principal

Greenwich Lifesciences Inc (NASDAQ: GLSI) — Perfil da empresa, notícias e dados financeiros

Logo de Greenwich Lifesciences Inc
GLSI Greenwich Lifesciences Inc
Greenwich Lifesciences Inc primary media
Perfil da empresa

Greenwich Lifesciences Inc

Greenwich Lifesciences (NASDAQ:GLSI) is a biopharmaceutical enterprise focused on the development and commercialization of therapeutics for breast cancer patients. The core of its operations lies in advancing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. With a clear objective to enhance survival rates and quality of life for breast cancer sufferers, the company leverages cutting-edge scientific research to push the boundaries of treatment possibilities. Greenwich Lifesciences is dedicated to bringing novel, life-saving therapies to market, aiming to transform the landscape of cancer care for women worldwide.

Resumo

Public USParticipação acionária
2006Ano de fundação
3Funcionários
Stafford, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Greenwich Lifesciences Inc

  • GP2 is a novel immunotherapy for preventing breast cancer recurrence.
  • Research into immunotherapies targeting various cancer types.
  • Development of precision medicine techniques for cancer treatment.
  • Collaboration with academic and research institutions to advance cancer immunotherapy studies.
  • Involvement in clinical trials to test the efficacy and safety of new cancer treatments.
  • Providing educational resources and support for cancer patients and healthcare professionals.

equipe executiva do Greenwich Lifesciences Inc

  • Snehal S. PatelCEO, CFO & Director
  • Eric RotheFounder & Independent Director
  • Frank Joseph DaughertyChief Medical Officer & Director
  • Jaye L. ThompsonVice President Clinical & Regulatory Affairs
  • Christine T. FischetteVP of Business Development

Comunicados recentes

O que a Greenwich Lifesciences Inc (GLSI) comunicou ao mercado, do mais recente para o mais antigo.

Principais indicadores financeiros

Resultados divulgados pela Greenwich Lifesciences Inc, em USD.

Cap. de mercado
302,1 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-1.6
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Greenwich Lifesciences Inc
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-19,4 mi-19,4 mi
0-17,6 mi-17,4 mi
0-9,3 mi-8,9 mi
0-8 mi-7,8 mi